PRVB News and Press, Provention Bio Inc. From 12/20/21

Provention Bio (NASDAQ:PRVB) has appointed Christina Yi as Chief Operations Officer and Benedict Osorio as Chief Quality Officer, responsible for all aspects of quality.  Ms. Yi most recently served as Chief Operating Officer at Vaxxinity developing vac...

Provention Bio Announces Leadership Team Expansion PR Newswire RED BANK, N.J. , Dec. 20, 2021 /PRNewswire/ -- December 20 , 2021— Provention Bio, Inc. (NASDAQ: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and pre...

Electric vehicle companies remained prominent in Monday's midday trading. Tesla (NASDAQ:TSLA) gained ground on an update of its Model S Plaid launch in China, while Rivian (NASDAQ:RIVN) plunged on news that a joint project with Ford (NYSE:F) has been canceled. Elsewhere, Alnylam Pharmaceutica...

Gainers: iSpecimen (NASDAQ:ISPC) +120%, MultiPlan (NYSE:MPLN) +21%, Provention Bio PRVB +20%, Stoke Therapeutics (NASDAQ:STOK) +16%, Star Equity STRR +14%. Losers: Gracell Biotechnologies (NASDAQ:GRCL) -31%, Aurinia Pharmaceuticals (NASDA...

Astra Space (NASDAQ:ASTR) +35% after successful commercial orbital launch iSpecimen (NASDAQ:ISPC) +26% selected by U.S. Government and private researchers to supply critical human biospecimens for advanced phase of COVID-19 research PainReform (NASDAQ:PRFX) +19%. Vonage Holding...

Provention Bio (NASDAQ:PRVB) soars 12% premarket after providing an update related to the Complete Response Letter (CRL) issued in July 2021 for Biologics License Application (BLA) for teplizumab. On November 18, 2021, the Company had a Type A meeting with the FDA to discuss th...

Provention Bio Provides Regulatory Update for Teplizumab At-Risk Type 1 Diabetes Approval Pathway PR Newswire RED BANK, N.J. , Nov. 22, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preven...

Provention Bio Appoints Jan Hillson, M.D., as Senior Vice President of Clinical Development PR Newswire RED BANK, N.J. , Nov. 17, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing i...

Provention Bio Puts Type 1 Diabetes to the Test with Pledge Campaign for Diabetes Awareness Month PR Newswire RED BANK, N.J. , Nov. 9, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and prevent...

Image source: The Motley Fool. Provention Bio, inc (NASDAQ: PRVB) Q3 2021 Earnings Call Nov 5, 2021 , 2:00 p.m. ET Operator Continue reading For further details see: Provention Bio, inc (PRVB) Q3 2021 Earnings Call Transcript